Rehmann Capital Advisory Group Decreases Stake in Pfizer Inc. (NYSE:PFE)

Rehmann Capital Advisory Group lowered its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 6.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 155,207 shares of the biopharmaceutical company's stock after selling 9,918 shares during the period. Rehmann Capital Advisory Group's holdings in Pfizer were worth $3,933,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Slagle Financial LLC increased its stake in Pfizer by 1.5% during the 1st quarter. Slagle Financial LLC now owns 74,748 shares of the biopharmaceutical company's stock valued at $1,894,000 after purchasing an additional 1,120 shares in the last quarter. Cornerstone Planning Group LLC grew its holdings in shares of Pfizer by 40.1% during the first quarter. Cornerstone Planning Group LLC now owns 2,549 shares of the biopharmaceutical company's stock valued at $65,000 after buying an additional 730 shares during the last quarter. Greenleaf Trust increased its position in shares of Pfizer by 6.9% during the first quarter. Greenleaf Trust now owns 252,749 shares of the biopharmaceutical company's stock valued at $6,405,000 after acquiring an additional 16,267 shares in the last quarter. CORDA Investment Management LLC. raised its holdings in Pfizer by 5.8% in the 1st quarter. CORDA Investment Management LLC. now owns 1,075,063 shares of the biopharmaceutical company's stock worth $27,242,000 after acquiring an additional 59,047 shares during the last quarter. Finally, New Insight Wealth Advisors bought a new position in Pfizer in the 1st quarter valued at approximately $3,450,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

PFE stock traded down $0.13 during trading on Friday, reaching $25.65. The company's stock had a trading volume of 34,838,317 shares, compared to its average volume of 41,815,665. The company's fifty day moving average is $23.86 and its 200-day moving average is $24.81. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The company has a market capitalization of $145.83 billion, a P/E ratio of 18.59, a price-to-earnings-growth ratio of 0.93 and a beta of 0.58. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter last year, the company earned $0.82 EPS. The firm's quarterly revenue was down 7.8% on a year-over-year basis. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 6.71%. Pfizer's payout ratio is 124.64%.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on PFE shares. UBS Group boosted their price target on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Jefferies Financial Group boosted their target price on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research report on Wednesday, May 21st. Berenberg Bank dropped their price target on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. Bank of America increased their price objective on shares of Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Finally, Redburn Atlantic cut their target price on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a research report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $28.55.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.